Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib plus chemotherapy as neoadjuvant therapy for adult osteosarcoma
ChiCTR2200062550Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in osteosarcoma (OS), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Tumor necrosis rate and Safety. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2200062550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062550.